ICON plc | Clinical Research Organisation (CRO) for Drug Development

Flow Cytometry for Driving Trials Forward

Engage assay experts with deep experience and expertise.

Charting the Managed Access Program Landscape

Plan for regulatory and operational challenges in managed access programs.

The Impact of AI on Outcomes Based Contracting

Understanding formulary decision maker & manufacturer challenges

Key Considerations in Chronic Pain Clinical Trials

Determine the right design, assessments and endpoints in your pain study

Featured Services

Site & Patient Solutions

Transforming recruitment through patient-centric trials and real-world, real-time data

Biosimilars

ICON can support product design, development and registration, regulatory support and commercialisation of Biosimilars.

Biotech

ICON provides full service outsourcing and flexible support for biotech specific needs such as due diligence and asset valuation.

Functional Resourcing

From recruitment of a single clinical professional to managing entire global functions.

ICON Insights

10 October 2019

Pharma ROI Restoration

Using Big Data and AI to return pharma productivity to sustainable levels.

01 October 2019

The Rare Disease Revolution

Emerging research approaches and real-world evidence are fulfilling the needs of rare disease patients with increased speed.

30 September 2019

Real World Evidence: The Evolving Views of Regulators and Payers

RWE is being used to provide a more comprehensive data set for regulators’ and payers’ use in approval and reimbursement decisions.

19 September 2019

Can AI improve R&D productivity enough to restore ROI to sustainable levels?

According to an ICON survey, artificial intelligence (AI) was considered the digital technology with the most potential to improve R&D productivity

16 September 2019

Key Considerations for Disease-Modifying Parkinson’s Disease Trials

Taking into consideration the lessons learned from Alzheimer’s disease studies could benefit the design of neuro-protective studies.

12 September 2019

Oncology Clinical Trials in Asia Pacific

The size and significance of the APAC market make clinical trials, on the cutting edge of oncology development, an attractive investment.

09 September 2019

The importance of the patient voice in the rare disease market

Orphan drugs, by nature, remain commercially underdeveloped, and as demand in the market increases, patients in clinical trials need to be considered.

09 September 2019

Adoptive Cellular Transfer (ACT): Novel Cancer Trials Demand That Participating Sites Act Differently

Sites participating in ACT trials need to be prepared with regulatory intelligence, scalable logistics, adequate resources and dedicated data management teams.

02 September 2019

Alzheimer’s in Clinical Trials

Attempting to develop casual treatment against the progression of Alzheimer’s disease has resulted in unparalleled series of failures for nearly 2 decades of drug development.

Services

Sectors

Therapeutics

Innovation

Insights

News & Events

About ICON

Developing medical communications specifically for nurses

How digital technologies will transform R&D productivity

Increasing complexity and declining ROI in drug development

Payer reliance on ICER assessments and perceptions on value-based pricing